CVE:RVV Revive Therapeutics (RVV) Stock Price, News & Analysis C$0.08 +0.01 (+14.29%) As of 07/22/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Revive Therapeutics Stock (CVE:RVV) Get Revive Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.08▼C$0.0950-Day RangeC$0.08▼C$0.0852-Week RangeC$0.07▼C$0.25Volume212,852 shsAverage Volume93,085 shsMarket CapitalizationC$5.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada. Read More Receive RVV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVV Stock News HeadlinesRevive Therapeutics Ltd RVVJune 26, 2026 | morningstar.comMRevive Therapeutics Announces Proposed Private PlacementJune 26, 2026 | theglobeandmail.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.July 5 at 1:00 AM | Weiss Ratings (Ad)Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical CountermeasuresMay 20, 2026 | usatoday.comRevive Therapeutics Provides Update of Key Nerve Agent Countermeasure StudyDecember 15, 2025 | financialpost.comFRevive Therapeutics Provides Update of Key Nerve Agent Countermeasure StudyNovember 21, 2025 | financialpost.comFRevive Therapeutics Extends Private Placement to Support Therapeutic ProgramsSeptember 20, 2025 | theglobeandmail.comRevive Therapeutics Updates on Nerve Agent Countermeasure StudyAugust 19, 2025 | theglobeandmail.comSee More Headlines RVV Stock Analysis - Frequently Asked Questions How have RVV shares performed this year? Revive Therapeutics' stock was trading at C$0.08 at the beginning of 2026. Since then, RVV shares have increased by 0.0% and is now trading at C$0.08. How do I buy shares of Revive Therapeutics? Shares of RVV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Revive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revive Therapeutics investors own include Aurora Cannabis (ACB), IntelGenx Technologies (IGXT), Plug Power (PLUG), Sorrento Therapeutics (SRNE), Green Organic Dutchman (TGOD) and Zoom Communications (ZM). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:RVV CIKN/A Webwww.revivethera.com Phone+1-905-6055535FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.14 Quick Ratio6.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.03 per share Price / Cash Flow3.18 Book ValueC$0.02 per share Price / Book4.21Miscellaneous Outstanding Shares72,411,000Free FloatN/AMarket CapC$5.79 million OptionableNot Optionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (CVE:RVV) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revive Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Revive Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
